Patents Examined by Umamaheswari Ramachandran
  • Patent number: 11324691
    Abstract: Provided are compositions and methods for treating rosacea and acne. Specifically, a gel or foam composition having a tetracycline antibiotic and uses thereof for treating rosacea and acne are provided.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: May 10, 2022
    Assignee: Journey Medical Corporation
    Inventors: Dov Tamarkin, Meir Eini, Yohan Hazot, Mitchell Shirvan, Tal Hetzroni Kedem, Rita Keynan
  • Patent number: 11324722
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: May 10, 2022
    Assignee: RVL Pharmaceuticals, Inc.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 11291204
    Abstract: A composition for and methods of preserving a topical cosmetic, toiletry or pharmaceutical formulation against microbiological contamination or growth are described in which the compositions used herein include at least one hydroxamic acid, salt or complex thereof, and the methods include addition of an effective amount of such compounds to a cosmetic, toiletry or pharmaceutical formulation. Compositions further including alkanediols and/or solubilizing agents in blends with hydroxamic acid are also described.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: April 5, 2022
    Assignee: INOLEX INVESTMENT CORPORATION
    Inventor: Daniel Winn
  • Patent number: 11286256
    Abstract: Provided herein are compounds and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of conditions associated with inhibition of HDAC (e.g,. HDAC2).
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: March 29, 2022
    Assignee: Alkermes, Inc.
    Inventors: Nathan Oliver Fuller, John A. Lowe, III
  • Patent number: 11278526
    Abstract: Methods for treatment of systemic lupus erythematosus (SLE” or “Lupus”) by administration of a modulator of sphingosine-1-phosphate receptor subtype 1 (S1P1), as well as compositions and methods related to the same, wherein such S1P1 modulators have the following general structure and wherein X and Y are as defined herein.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 22, 2022
    Assignee: RECEPTOS LLC
    Inventors: Fiona Lorraine Scott, Kristen R. Taylor Meadows, Robert Peach
  • Patent number: 11273136
    Abstract: An object of the present invention is to increase a protein content in milk of a lactating cow. When 5-ALA, an amino acid, or ALAs which are derivatives thereof or salts thereof, are mixed with a feed and administered to a lactating cow without being treated such as coating, a lactation yield remained substantially unchanged but the obtained milk had significantly high proportion (%) of proteins, particularly casein, when compared with milk collected from milk cows who had consumed a conventional feed.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: March 15, 2022
    Assignee: neopharma Japan Co. LTD.
    Inventors: Shin Taniguchi, Yoko Noguchi, Kan Sato
  • Patent number: 11273151
    Abstract: The present invention relates to methods of treating a tumor or treating cancer in a subject having a p53 DNA contact mutation that involve administering, to the subject, a ROCK inhibitor. Also disclosed is a method of identifying a subject as a candidate for such treatment.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 15, 2022
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventors: Stuart Aaronson, Albino Troilo, Davide Esposito
  • Patent number: 11260038
    Abstract: The present invention features methods and compositions for the intranasal, sublingual, and subcutaneous administration of bumetanide for the treatment of subjects suffering from edema refractory to oral diuretics.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 1, 2022
    Assignee: RESQ Pharmaceuticals LLC
    Inventors: Balasingam Radhakrishnan, Ben Esque, Wei Lin, Andrew Xian Chen
  • Patent number: 11253512
    Abstract: A opioid taper regimen, and its method of manufacture, for use in a method of opioid reduction leading to abstinence. Said regimen is administered within the range of 2 to 4 years, or more. The regimen comprises novel approaches to common problems encountered during tapers of low dose opioid addiction. The reduction regimen is generally linear; reduces the dosage level once per week; doses every six hours; reduces doses by steps in the range of about 0.001 to 0.0500 mg; has, near the end, ten weeks of doses of about 0.0025 mg buprenorphine q.i.d.; followed by four or more weeks of placebos. Instructions for manufacture of doses that differ by 0.0025 mg and 0.0050 mg buprenorphine are specified.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: February 22, 2022
    Inventor: Joseph Leon Grossman
  • Patent number: 11246867
    Abstract: The invention relates to oral pharmaceutical compositions comprising pimobendan pharmaceutically active compound. It also relates to a method for preparing the same uses thereof.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: February 15, 2022
    Assignee: Ceva Sante Animale
    Inventors: Rosita Garcia, Romain Charles
  • Patent number: 11246886
    Abstract: The present application relates to the treatment of autism and autism spectrum disorders using biotin compositions.
    Type: Grant
    Filed: September 4, 2019
    Date of Patent: February 15, 2022
    Assignee: NUTRITION 21, LLC
    Inventor: James R. Komorowski
  • Patent number: 11241410
    Abstract: A method for the treatment of a coronavirus disease, including administering to a subject in need thereof of an anti-pathogenic compound, such that the anti-pathogenic compound is derived from an herbal extract.
    Type: Grant
    Filed: July 31, 2020
    Date of Patent: February 8, 2022
    Inventors: Amanuel Tesfazion, Lydia Seifu, Meried Bezuneh
  • Patent number: 11241431
    Abstract: The present invention relates to derivatives of formula (I) wherein (R1)n, R2, R3, R4a, R4b, R5a, R5b and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as modulators of the prostaglandin 2 receptors EP2 and/or EP4.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: February 8, 2022
    Assignee: IDORSIA PHARMACEUTICALS LTD
    Inventors: Heinz Fretz, Isabelle Lyothier, Julien Pothier, Sylvia Richard-Bildstein, Thierry Sifferlen, Lorenza Wyder Peters, Davide Pozzi, Olivier Corminboeuf
  • Patent number: 11234965
    Abstract: The present invention provides methods for inhibiting postoperative inflammatory conditions following ophthalmologic surgical procedures by administering intraocularly during an ophthalmologic surgical procedure a solution including a nonsteroidal anti-inflammatory agent and an alpha-1 adrenergic mydriatic agent, such as a liquid irrigation solution of ketorolac and phenylephrine.
    Type: Grant
    Filed: February 14, 2019
    Date of Patent: February 1, 2022
    Assignee: OMEROS CORPORATION
    Inventors: Gregory A. Demopulos, Vincent A. Florio
  • Patent number: 11229643
    Abstract: The present invention relates to a pharmaceutical combination comprising an FGFR4 inhibitor and a bile acid sequestrant, to the use of the pharmaceutical combination in the treatment of cancer, to the use of a bile acid sequestrant to reduce or mitigate side-effects associated with FGFR4 inhibition therapy.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: January 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Robin Alec Fairhurst, Diana Graus Porta, Jacqueline Kinyamu-Akunda, Andreas Joerg Mahl, Luigi Manenti, Andreas Weiss, Armin Wolf, Kuno Wuersch
  • Patent number: 11219615
    Abstract: The present disclosure is directed to compositions comprising oxymetazoline and methods of treating various eye disorders related to drooping eyelids, such as ptosis, in a subject comprising administering to the subject compositions comprising oxymetazoline.
    Type: Grant
    Filed: March 8, 2021
    Date of Patent: January 11, 2022
    Assignee: RVL PHARMACEUTICALS, INC.
    Inventors: Tina deVries, David Jacobs
  • Patent number: 11213481
    Abstract: A method of subcutaneous delivery of a drug or a therapeutic agent to a subject to treat a localized condition, the method including obtaining a liquid composition including the drug or the therapeutic agent dissolved in a tumescent solution, wherein the tumescent solution includes the drug or the therapeutic agent a vasoconstrictor; and a pharmaceutically acceptable carrier; and delivering a mass of the liquid composition subcutaneously to a localized tissue in the subject, wherein the drug or the therapeutic agent treats the localized condition in the localized tissue, wherein a concentration of the drug or the therapeutic agent subcutaneously delivered exceeds a concentration of the drug or the therapeutic agent that can be safely achieved by intravenous delivery, and wherein an amount of the drug or the therapeutic agent located at an outer boundary of the mass of fluid and available for absorption is less than an amount of the drug or the therapeutic agent located within a central portion of the mass of
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: January 4, 2022
    Assignee: HK Pharma
    Inventor: Jeffrey Alan Klein
  • Patent number: 11207306
    Abstract: Non-aqueous liquid compositions comprising nimodipine having improved stability over aqueous compositions comprising nimodipine are provided herein. Methods of improving neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms with the non-aqueous liquid compositions of the present invention are also detailed herein.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: December 28, 2021
    Assignee: Arbor Pharmaceuticals, LLC
    Inventor: Hugh Greg Thomas
  • Patent number: 11191746
    Abstract: The present invention relates to a composition for inhibiting the growth of cancer stem cells, which includes ciclesonide or a pharmaceutically acceptable salt thereof as an active ingredient, a pharmaceutical composition or food composition for inhibiting cancer metastasis, or treating or preventing cancer, which includes the composition, and the like. Ciclesonide of the present invention inhibits the growth of breast cancer cells and lung cancer cells, and inhibits the formation of breast cancer stem cells and lung cancer stem cells.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: December 7, 2021
    Assignee: JEJU NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Dong-sun Lee, Hack Sun Choi
  • Patent number: 11173154
    Abstract: A method of treating a disease, condition or state characterized by an exacerbated immune response is disclosed. The method of treatment can include topoisomerase I inhibitors and pharmaceutical compositions comprising topoisomerase I inhibitors, which can be administered alone or in combination with another therapeutic agent. The method can be used to treat a range of diseases, disorders, conditions and states, including but not limited to sepsis, acute liver failure, and endotoxic and/or exotoxic shock. These diseases, disorders, conditions and states can be caused by a variety of microorganisms and/or portions of microorganisms including but not limited to Ebola virus, Lassa virus, Influenza virus, Legionella, lipopolysaccharide (LPS), and bacterial endotoxins/exotoxins.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: November 16, 2021
    Assignee: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
    Inventor: Ivan Marazzi